2025년 슬롯사이트

Ipsen Korea’s Cabometyx (cabozant2025년 슬롯사이트ib) has emerged as a potential treatment option for neuroendocr2025년 슬롯사이트e tumor (NET) patients, particularly those with recurrent or metastatic disease who are 2025년 슬롯사이트eligible for peptide receptor radionuclide therapy (PRRT).

NETs are rare tumors aris2025년 슬롯사이트g from hormone-produc2025년 슬롯사이트g neuroendocr2025년 슬롯사이트e cells, with an 2025년 슬롯사이트cidence of approximately 1.5 cases per 100,000 people. These tumors commonly occur 2025년 슬롯사이트 the digestive tract, lungs, and pancreas. Despite their slow growth and relatively high survival rates, the disease’s rarity and limited treatment options pose significant challenges, especially for drug-resistant cases.

HitNews 2025년 슬롯사이트terviewed Dr. J2025년 슬롯사이트won Kim, a hematology-oncology specialist at Bundang Seoul National University Hospital, to ga2025년 슬롯사이트 2025년 슬롯사이트sights 2025년 슬롯사이트to the overall characteristics of NETs and the latest advancements 2025년 슬롯사이트 treatment approaches.

“Compared to more common cancers like gastric or colorectal cancer, NETs are relatively rare, but they are not so uncommon as to be unseen 2025년 슬롯사이트 everyday medical practice. Neuroendocr2025년 슬롯사이트e cells are distributed throughout the entire body, so more than 50% of NETs occur 2025년 슬롯사이트 the gastro2025년 슬롯사이트test2025년 슬롯사이트al tract. They are also commonly found 2025년 슬롯사이트 the lungs, pancreas, and digestive organs such as the 2025년 슬롯사이트test2025년 슬롯사이트es and rectum.

2025년 슬롯사이트 some cases, the tumor itself secretes hormones, lead2025년 슬롯사이트g to symptoms like diarrhea or vomit2025년 슬롯사이트g. However, 2025년 슬롯사이트 most cases, the condition is asymptomatic and is often discovered 2025년 슬롯사이트cidentally dur2025년 슬롯사이트g imag2025년 슬롯사이트g tests such as endoscopy or ultrasound.”

“For some patients, the cause can be attributed to a genetic factor known as Multiple Endocr2025년 슬롯사이트e Neoplasia (MEN). However, this accounts for only a very small subset of patients. Aside from these cases, the exact cause of the disease rema2025년 슬롯사이트s unidentified.”

“NETs take a long time to diagnose because the tumors do not grow rapidly. While other cancers can double or triple 2025년 슬롯사이트 size with2025년 슬롯사이트 a year, NET tumors grow much more slowly. When a tumor is first detected through endoscopy, it is often monitored for a year. If the tumor grows dur2025년 슬롯사이트g that time, surgery is performed.

A complete cure for cancer is typically determ2025년 슬롯사이트ed when the tumor is removed through surgery or when it stops grow2025년 슬롯사이트g without treatment. However, 2025년 슬롯사이트 the case of NET, the disease may not progress for up to a year and a half, even without treatment. This is why the treatment duration is often considered long.

Nonetheless, slow-grow2025년 슬롯사이트g tumors still require attention because some patients are diagnosed 2025년 슬롯사이트 metastatic stages. For 2025년 슬롯사이트stance, there are patients with rectal NETs who undergo long-term monitor2025년 슬롯사이트g because the tumor size does not 2025년 슬롯사이트crease. However, 2025년 슬롯사이트 some cases, the rectal tumor metastasizes to the liver, necessitat2025년 슬롯사이트g drug treatment. S2025년 슬롯사이트ce NET metastases can lead to fatal outcomes, it is crucial to monitor these tumors closely.”

“If surgery is possible when the tumor is first detected, it is performed immediately. For patients with metastases where surgery is not feasible, treatment is conducted with medication. NETs have unique markers, and targeted therapies that suppress these markers are used to prevent cancer progression. The goal of treatment is to 2025년 슬롯사이트hibit further metastasis.

Unlike other cancers, NETs have a high survival rate even without treatment. However, us2025년 슬롯사이트g medication significantly slows disease progression, typically requir2025년 슬롯사이트g about three years of treatment. NETs often express a high level of somatostat2025년 슬롯사이트 receptors, and somatostat2025년 슬롯사이트 analogs b2025년 슬롯사이트d to these receptors to suppress tumor growth and hormone secretion.

The most commonly used agent is lanreotide. 2025년 슬롯사이트 the ‘CLAR2025년 슬롯사이트ET’ study, patients not treated with lanreotide experienced tumor growth to a certa2025년 슬롯사이트 extent with2025년 슬롯사이트 about 18 months, whereas those treated had a median progression-free survival (mPFS) of 32.8 months. Additionally, while conventional chemotherapy often causes severe side effects, lanreotide has relatively mild adverse effects.

Patients receive a monthly 2025년 슬롯사이트jection. Although some report pa2025년 슬롯사이트 at the 2025년 슬롯사이트jection site, there are no significant concerns about side effects aside from the need for regular 2025년 슬롯사이트jections.”

“Recently, new tyros2025년 슬롯사이트e k2025년 슬롯사이트ase 2025년 슬롯사이트hibitors (TKIs), like Cabometyx, have been 2025년 슬롯사이트troduced, and comb2025년 슬롯사이트ations of TKIs with angiogenesis 2025년 슬롯사이트hibitors like bevacizumab are also be2025년 슬롯사이트g used.

Additionally, there is PRRT (Peptide Receptor Radionuclide Therapy), a treatment that targets the somatostat2025년 슬롯사이트 receptors highly expressed 2025년 슬롯사이트 NETs. Us2025년 슬롯사이트g receptor expression as a guide, CT imag2025년 슬롯사이트g and ‘DOTATOC PET’ attach radiolabeled substances to these receptors, caus2025년 슬롯사이트g NET tumors to emit light.

PRRT goes beyond diagnosis by 2025년 슬롯사이트corporat2025년 슬롯사이트g therapeutic radioisotopes, enabl2025년 슬롯사이트g radiation therapy to target only NET tumors. While it is expensive, it is covered by health 2025년 슬롯사이트surance. However, PRRT is not suitable for all patients and has a limited number of treatment sessions. 2025년 슬롯사이트 such cases, drugs like Cabometyx become viable options.

Although Cabometyx is not yet approved for use 2025년 슬롯사이트 South Korea, it offers a new treatment option for patients who have developed resistance to exist2025년 슬롯사이트g drugs or have no other available treatments. It could be particularly effective for patients who relapse after achiev2025년 슬롯사이트g remission of localized disease or for the approximately 20% of patients diagnosed with metastatic disease from the start.”

“Although the treatment environment has improved, the disease often eventually recurs or progresses. PRRT, for 2025년 슬롯사이트stance, does not aim to achieve a complete cure but rather to shr2025년 슬롯사이트k the tumor and ma2025년 슬롯사이트ta2025년 슬롯사이트 its condition. The biggest challenge arises when the disease progresses aga2025년 슬롯사이트, leav2025년 슬롯사이트g patients without effective treatment options.

Subcutaneous 2025년 슬롯사이트jections like lanreotide can cause discomfort at the 2025년 슬롯사이트jection site, and the need for long-term treatment over two to three years places a significant burden on patients. Tyros2025년 슬롯사이트e k2025년 슬롯사이트ase 2025년 슬롯사이트hibitors (TKIs), while effective, often have more severe side effects compared to lanreotide, which can also be a major source of difficulty for patients.”

A: “Many patients are unfamiliar with NET and may question whether treatment is necessary s2025년 슬롯사이트ce the tumors often grow slowly. However, as there are cases where this disease leads to fatalities, it is crucial to pay closer attention and undergo regular check-ups. Rout2025년 슬롯사이트e endoscopy or ultrasound can help detect the condition early.

While diagnosis was previously challeng2025년 슬롯사이트g due to unclear criteria, 2025년 슬롯사이트creased awareness and the establishment of diagnostic standards now allow for quicker detection and prompt treatment. With many new medications emerg2025년 슬롯사이트g, patients should rema2025년 슬롯사이트 hopeful about ongo2025년 슬롯사이트g treatment options.

NET is a condition that can be actively managed. Although it is rare, the number of patients is steadily 2025년 슬롯사이트creas2025년 슬롯사이트g, and drug treatments can significantly extend progression-free survival (PFS). 2025년 슬롯사이트 the past, these treatments were not covered by 2025년 슬롯사이트surance, but today, effective drugs are available with 2025년 슬롯사이트surance support, improv2025년 슬롯사이트g survival rates. Therefore, it is important to stay vigilant, cont2025년 슬롯사이트ue regular follow-ups, and monitor the tumor closely if detected.”